The content of matrix metalloproteinases 7 and 9 was significantly increased, while the content of metalloproteinase 2 was reduced in ovarian cancer tissue compared to benign tumors. In blood serum from patients with ovarian cancer, the concentrations of matrix metalloproteinases 7 and 9 and their type 1 tissue inhibitor were significantly elevated, while the concentration of matrix metalloproteinase 2 was reduced compared to the corresponding parameters in healthy women. After chemotherapy, tissue and serum concentrations of metalloproteinases and their inhibitor in patients practically returned to normal. A significant positive correlation between serum levels of matrix metalloproteinases 7 and 9 and tissue inhibitor of metalloproteinases-1 in patients with ovarian cancer and the size of primary tumor (ultrasound examination) and a positive correlation between these parameters and the concentration of classical ovarian cancer marker CA-125 were demonstrated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
E. C. Gershtein, E. A. Korotkova, A. M. Shcherbakov, et al., Byull. Eksp. Biol. Med., 143, No. 3, 438–441 (2007).
K. Q. Cai, W.L. Yang, C. D. Capo-Chichi, et al., Mol. Carcinog., 46, No. 2, 130–143 (2007).
A. Demeter, I. Sziller, Z. Csapo, et al., Anticancer Res., 25, No. 4, 2885–2889 (2005).
E. I. Deryugina and J. P. Quigley, Cancer Met. Rev., 25, No. 1, 9–34 (2006).
A. A. Kamat, M. Fletcher, L. M. Gruman, et al., Clin. Cancer Res., 12, No. 6, 1707–1714 (2006).
M. Maatta, A. Talvensaari-Mattila, T. Turpeenniemi-Hujanen, and M. Santala, Anticancer Res., 27, No. 4C, 2753–2758 (2007).
S. Ozalp, H. M. Tanir, O. T. Yalcin, et al., Eur. J. Gynaecol. Oncol., 24, No. 5, 417–420 (2003).
M. Perigny, I. Bairati, I. Harvey, et al., Am. J. Clin. Pathol., 129, No. 2, 226–231 (2008).
N. Ramnath and P. J. Creaven, Curr. Oncol. Rep., 6, No. 2, 96–102 (2004).
M. Rauvala, U. Puistola, and T. Turpeenniemi-Hujanen, Gynecol. Oncol., 99, No. 3, 656–663 (2005).
M. Rauvala, T. Turpeenniemi-Hujanen, and U. Puistola, Anticancer Res., 26, No. 6C, 4779–4784 (2006).
S. Sillanpaa, M. Anttila, K. Suhonen et al., Tumour Biol., 28, No. 5, 280–289 (2007).
S. Sillanpaa, M. Anttila, K. Voutilainen, et al., Gynecol. Oncol., 104, No. 2, 296–303 (2007).
S. M. Sillanpaa, M. A. Anttila, K. A. Voutilainen, et al., Int. J. Cancer, 119, No. 8, 1792–1799 (2006).
K. Zaman, R. Driscoll, D. Hahn, et al., Ibid, 118, No. 3, 755–764 (2006).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 149, No. 5, pp. 562–565, May, 2010
Rights and permissions
About this article
Cite this article
Gershtein, E.S., Levkina, N.V., Digayeva, M.A. et al. Matrix Metalloproteinases 2, 7, and 9 and Tissue Inhibitor of Metalloproteinases-1 in Tumors and Serum of Patients with Ovarian Neoplasms. Bull Exp Biol Med 149, 628–631 (2010). https://doi.org/10.1007/s10517-010-1010-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-010-1010-4